Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography

  • Authors:
    • Naoko Takeuchi
    • Mitsutaka Fukumoto
    • Akihito Nishioka
    • Naoki Akagi
    • Yoriko Murata
    • Seisho Takeuchi
    • Yasuhiro Ogawa
    • Shoji Yoshida
  • View Affiliations

  • Published online on: January 1, 2002     https://doi.org/10.3892/ijo.20.1.53
  • Pages: 53-58
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have investigated the usefulness of dual-isotope single photon emission computed tomography (SPECT) for predicting the response to chemotherapy in patients with breast cancer. Twenty-five patients with breast cancer were analyzed by SPECT using both 99m-technetium-tetrofosmin (99mTc-TF) and 201-thallium-chloride (201Tl). The relationship between response to chemotherapy and retention of each tracer was analyzed. 99mTc-TF retention was significantly higher in responders (42.0±37.9) than in non-responders (-11.3±34.6) (p=0.003). Ten of 13 patients (76.9%) with high 99mTc-TF retention (>15%) showed good response to chemotherapy, whereas 11 of 12 patients (91.7%) with low 99mTc-TF retention (<15%) did not respond to the therapy. The overall predictability to the response to chemotherapy was 84.0%. 201Tl retention (responders, 47.5±60.2% vs. non-responders, 55.8±45.0%; p=0.443) was not useful in therapeutic prediction, but was required to identify the lesion on the SPECT image. This is the first report to find that dual-isotope SPECT using 99mTc-TF and 201Tl is useful in predicting the response to chemotherapy in patients with breast cancer. Low 99mTc-TF retention is a strong predictor of therapeutic resistance, and high 99mTc-TF retention suggests a favorable response to chemotherapy.

Related Articles

Journal Cover

January 2002
Volume 20 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, Ogawa Y and Yoshida S: Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol 20: 53-58, 2002.
APA
Takeuchi, N., Fukumoto, M., Nishioka, A., Akagi, N., Murata, Y., Takeuchi, S. ... Yoshida, S. (2002). Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. International Journal of Oncology, 20, 53-58. https://doi.org/10.3892/ijo.20.1.53
MLA
Takeuchi, N., Fukumoto, M., Nishioka, A., Akagi, N., Murata, Y., Takeuchi, S., Ogawa, Y., Yoshida, S."Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography". International Journal of Oncology 20.1 (2002): 53-58.
Chicago
Takeuchi, N., Fukumoto, M., Nishioka, A., Akagi, N., Murata, Y., Takeuchi, S., Ogawa, Y., Yoshida, S."Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography". International Journal of Oncology 20, no. 1 (2002): 53-58. https://doi.org/10.3892/ijo.20.1.53